ARTICLE | Company News
MedImmune Inc., Targesome deal
February 26, 2001 8:00 AM UTC
The companies will combine MEDI's Vitaxin, a humanized antibody angiogenesis inhibitor, with Targesome's nanoparticle technology to develop a targeted nanoparticle that delivers either therapeutics or...